NCT00725348View on ClinicalTrials.gov

An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

December 31, 2006

Conditions

Psoriasis

Interventions

DRUG

Talarozole

1.0 mg oral dose per day

Trial Locations (2)

Unknown

Academisch Ziekenhuis Maastricht, Maastricht

Universitair Medisch Centrum Nijmegen Sint Radboud, Nijmegen

All Listed Sponsors

lead

Stiefel, a GSK Company

INDUSTRY

NCT00725348 - An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis | Biotech Hunter | Biotech Hunter